Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Feb;75(2):e13857.
doi: 10.1111/ijcp.13857. Epub 2020 Dec 4.

Effects of mirabegron on JJ stent-related symptoms: A multicentric study

Onder Cinar  1 , Yiloren Tanidir  2 , Selcuk Ozer  3 , Sezer Cizmeci  4 , Oguzcan Erbatu  5 , Turan Ozdemir  6 , Reha Girgin  1 , Sakir Ongun  4 , Oktay Ucer  5 , Fuat Kizilay  6 , Volkan Sen  7 , Bora Irer  8 , Ozan Bozkurt  3 ; Aegean Study Group of the Society of Urological Surgery
Affiliations
Multicenter Study

Effects of mirabegron on JJ stent-related symptoms: A multicentric study

Onder Cinar et al. Int J Clin Pract. 2021 Feb.

Abstract

Aims of the study: To investigate the effect of mirabegron 50 mg/daily for JJ stent-related symptoms after ureteroscopic stone surgery.

Methods: Medical records of 145 patients who were given a single daily oral dose of 50 mg of mirabegron for relieving stent-related symptoms were retrospectively analysed. Demographic and clinical data and stone parameters were recorded. All participants completed the Turkish version of the Ureter Symptom Score Questionnaire (USSQ-T) on the postoperative 7th day, and again after at least 3 weeks, before JJ stent removal. The severity of stent-related symptoms was statistically compared before and after the mirabegron treatment.

Results: The mean urinary symptoms score decreased significantly from 30.87 ± 9.43 to 22.61 ± 6.78 (P < .0001), mean body pain score decreased significantly from 21.82 ± 11.22 to 14.03 ± 7.52 (P < .0001), mean work performance score decreased from 10.50 ± 8.61 to 7.02 ± 6.51 (P < .0001) and mean general health score decreased significantly from 15.43 ± 6.50 to 11.12 ± 3.70 (P < .0001). The mean sexual matters score significantly decreased from 3.88 ± 3.40 to 2.48 ± 2.03 (P < .0001), the additional problem score decreased from 9.31 ± 4.61 to 6.51 ± 2.83 (P < .0001) and the overall quality of life (QoL) score decreased from 5.18 ± 1.94 to 4.23 ± 1.71 after mirabegron use (P < .0001).

Conclusion: Daily use of 50 g of mirabegron significantly improved stent-related symptoms, sexual matters and quality of life.

Keywords: mirabegron; pain; stent-related discomfort; ureteral stent.

PubMed Disclaimer

References

REFERENCES

    1. Beysens M, Tailly TO. Ureteral stents in urolithiasis. Asian J Urol. 2018;5(4):274-286.
    1. Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG. Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002;59:511-516.
    1. Bolat MS, Akdeniz E, Asci R, Erdemir F, Cinar O, Tomak L. Ureterorenoscopy with stenting and its effect on male sexual function: a controlled randomised prospective study. Andrologia. 2017;49(9):e12746. https://doi.org/10.1111/and.12746
    1. Miyaoka R, Monga M. Ureteral stent discomfort: etiology and management. Indian J Urol. 2009;25:455-460.
    1. Vega Vega A, García Alonso D, García Alonso CJ. Characterization of urinary tract symptoms and quality of life in patients with double-pig-tailed ureteral stents. Actas Urol Esp. 2007;31:738-742.

Publication types

LinkOut - more resources